Equitable Access to High-Cost Pharmaceuticals
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy...
Leider schon ausverkauft
208.99 €
versandkostenfrei
104 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Equitable Access to High-Cost Pharmaceuticals “
Weitere Produktinformationen zu „Equitable Access to High-Cost Pharmaceuticals “
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.
Bibliographische Angaben
- Herausgegeben:Babar, Zaheer-Ud-Din
- Verlag: Academic Press
- EAN: 9780128119457
Autoren-Porträt
Professor Zaheer-Ud-Din Babar is Professor in Medicines and Healthcare and the Director of Centre of Pharmaceutical Policy and Practice Research at the University of Huddersfield, United Kingdom. He is globally known for his work in pharmaceutical policy and practice, including quality use of medicines, clinical pharmacy practice, access to medicines and issues related to pharmacoeconomics. He has published in high impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for World Health Organization, Royal Pharmaceutical Society, Health Action International, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic evaluation of pharmacy services", "Pharmaceutical prices in the 21st century?, "Pharmaceutical policies in countries with developing healthcare systems ", "Global Pharmaceutical Policy?, "Pharmacy Practice Research Methods? and "Encyclopedia of Pharmacy Practice and Clinical Pharmacy?. Published by Elsevier and Adis/Springer, the work is used in curriculum design, policy development and for referral all around the globe. Professor Babar is also the Editor-in-Chief of BMC Journal of Pharmaceutical Policy and Practice and can be contacted at z.babar@hud.ac.uk
Inhaltsverzeichnis zu „Equitable Access to High-Cost Pharmaceuticals “
1. Access to High Cost Medicines: An Overview 2. Health Technology Assessment 3. High-Cost Medicines in England 4. Managed Entry Agreements and High Cost Medicines (European Perspective) 5. Setting a Public Health Agenda to Support Access to High-Cost Medicines 6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines 7. Access to High Price Medicines in Portugal 8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda 9. Equitable Access to Biosimilars: An Overview 10. Access to High-Cost Medicines in Europe 11. Access to High-Cost Medicines in Australia 12. Access to High-Cost Medicines in New Zealand 13. Access to High-Cost Medicines in Wales
Kommentar zu "Equitable Access to High-Cost Pharmaceuticals"
0 Gebrauchte Artikel zu „Equitable Access to High-Cost Pharmaceuticals“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Equitable Access to High-Cost Pharmaceuticals".
Kommentar verfassen